CDC Warns Drug-Resistant Fungus Candida Auris Cases Rising as FDA Approves First mRNA Flu Vaccine

Three important health updates are drawing attention this week: a rise in drug-resistant Candida auris cases, FDA approval of Moderna’s first mRNA flu vaccine, and growing concern about wildfire smoke exposure during pregnancy.

As of July 25, the CDC reported 3,437 clinical Candida auris cases across 27 states. The yeast is primarily a healthcare-associated threat, affecting people who are hospitalized, medically fragile, or living in long-term care facilities. Some strains resist multiple antifungal medicines, making infection prevention and early detection essential. CDC surveillance

The FDA has also approved MFLUSIVA, Moderna’s seasonal mRNA flu vaccine, for adults 50 and older. Clinical data indicate it was approximately 27% more effective than a standard-dose flu vaccine in preventing laboratory-confirmed influenza-like illness. Traditional approval covers adults ages 50–64, while approval for adults 65 and older follows an accelerated pathway. FDA approval and clinical review

Meanwhile, research shows wildfire smoke is eroding some air-quality gains made through reductions in traffic and industrial pollution. Prenatal exposure to fine particles from wildfire smoke has been associated with higher risks of preterm birth and low birth weight, with disproportionate burdens in low-income, rural, and Indigenous communities. Research summary EPA guidance

For households, check local health alerts, ask a clinician about flu vaccination options, and use clean indoor air practices during smoke events. Pregnant people should follow guidance from their healthcare provider and check AirNow’s air-quality reports.

What health questions are affecting your neighborhood? Share your experience with Brownstone Worldwide.